SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01728025

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine

The purpose of this study is to determine whether ranolazine will reduce the risk of arrhythmic events in patients with long QT syndrome type 3.

NCT01728025 Long QT Syndrome Type 3
MeSH: Long QT Syndrome Syndrome

1 Interventions

Name: Ranolazine

Type: Drug

Ranolazine


Primary Outcomes

Measure: Number of participants with syncope and/or documented ventricular arrhythmia

Time: 5 years

Secondary Outcomes

Measure: Change in corrected QT interval

Time: within 30 days of initiation of Ranolazine treatment

Purpose: Prevention

Single Group Assignment


There is one SNP

SNPs


1 D1790G

Inclusion Criteria: - Long QT patients with genetic confirmation of carrier-status for the D1790G mutation in the SCN5A gene - Corrected QT interval > 460 msec Exclusion Criteria: - Need for therapy with medications that are potent or moderately potent CYP3A inhibitors (such as ketoconazole, diltiazem, verapamil, macrolide antibiotics or HIV protease inhibitors) Inclusion Criteria: - Long QT patients with genetic confirmation of carrier-status for the D1790G mutation in the SCN5A gene - Corrected QT interval > 460 msec Exclusion Criteria: - Need for therapy with medications that are potent or moderately potent CYP3A inhibitors (such as ketoconazole, diltiazem, verapamil, macrolide antibiotics or HIV protease inhibitors) Long QT Syndrome Type 3 Long QT Syndrome Syndrome null --- D1790G ---

Inclusion Criteria: - Long QT patients with genetic confirmation of carrier-status for the D1790G mutation in the SCN5A gene - Corrected QT interval > 460 msec Exclusion Criteria: - Need for therapy with medications that are potent or moderately potent CYP3A inhibitors (such as ketoconazole, diltiazem, verapamil, macrolide antibiotics or HIV protease inhibitors) Inclusion Criteria: - Long QT patients with genetic confirmation of carrier-status for the D1790G mutation in the SCN5A gene - Corrected QT interval > 460 msec Exclusion Criteria: - Need for therapy with medications that are potent or moderately potent CYP3A inhibitors (such as ketoconazole, diltiazem, verapamil, macrolide antibiotics or HIV protease inhibitors) Long QT Syndrome Type 3 Long QT Syndrome Syndrome null --- D1790G --- --- D1790G ---



HPO Nodes